Abstract
Genetic Engineering & Biotechnology NewsVol. 42, No. 12 DepartmentsEnsuring the Purity of Gene Therapy Products and VaccinesSCIEX describes how the unique HCP challenges posed by gene therapies and RNA vaccines may be addressed with LC-MS technologyKerstin PohlKerstin PohlKerstin Pohl is Senior Manager, Cell & Gene Therapy and Nucleic Acids, SCIEX. Website: www.sciex.com.Search for more papers by this authorPublished Online:9 Dec 2022https://doi.org/10.1089/gen.42.12.10AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 42Issue 12Dec 2022 Information© 2022 by GEN PublishingTo cite this article:Kerstin Pohl.Ensuring the Purity of Gene Therapy Products and Vaccines.Genetic Engineering & Biotechnology News.Dec 2022.27-29.http://doi.org/10.1089/gen.42.12.10Published in Volume: 42 Issue 12: December 9, 2022PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
